Sunbio Inc. (067370)
Market Closed
11 Aug, 06:30
KRX SM KRX SM Primary ₩
6,700. 00
+120
+1.8237%
₩
77.51B Market Cap
- P/E Ratio
300% Div Yield
19,396 Volume
- Eps
₩ 6,580
Previous Close Want to track 067370 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
067370 closed today higher at ₩6,700, an increase of 1.8237% from yesterday's close, completing a monthly increase of 1.0558% or ₩70. Over the past 12 months, 067370 stock gained 18.1658%.
067370 is not paying dividends to its shareholders.
Sunbio Inc. has completed 1 stock splits, with the recent split occurring on Jan 07, 2021.
The company's stock is traded on one exchange.
Sunbio Inc. (067370) FAQ
What is the stock price today?
The current price is ₩6,700.00.
On which exchange is it traded?
Sunbio Inc. is listed on KRX SM.
What is its stock symbol?
The ticker symbol is 067370.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 300%.
What is its market cap?
As of today, the market cap is 77.51B.
Has Sunbio Inc. ever had a stock split?
Sunbio Inc. had 1 splits and the recent split was on Jan 07, 2021.
Sunbio Inc. Profile
| Biotechnology Industry | Healthcare Sector | - CEO | KRX SM Exchange | - ISIN |
| KR Country | - Employees | 27 Dec 2023 Last Dividend | 7 Jan 2021 Last Split | - IPO Date |
Overview
SunBio, Inc. is a pioneering South Korean biotech company with a worldwide presence in the development, production, and sale of biosimilar and biopharmaceutical products, along with medical devices. Utilizing its proprietary pegylation technologies, SunBio aims to advance medical treatments and therapies. The company is engaged in the creation of products that cater to various health conditions, including chronic anemia, brain stroke, and dry mouth syndrome. With its headquarters located in Gunpo, South Korea, SunBio is at the forefront of biotechnological innovation, delivering healthcare solutions globally.
Products and Services
- PEG-filgrastim: This biosimilar product by SunBio is developed to stimulate white blood cell production, aiding patients undergoing chemotherapy to fight off infections more effectively.
- PEG-EPO: Currently in the preclinical stage, this biosimilar aims to treat anemia associated with chronic kidney disease by stimulating the bone marrow to produce more red blood cells.
- Uricase (Preclinical Stage): Targeting gout, this enzyme-based treatment is designed to break down uric acid, potentially providing relief for patients with high uric acid levels in the blood.
- MucoPEG: A medical device created for the treatment of dry mouth syndrome, MucoPEG leverages advanced technology to provide relief to patients suffering from xerostomia, improving their quality of life.
- SynoGEL: A viscosupplement intended for the management of arthritic knee conditions, SynoGEL mimics the lubricating and shock-absorbing properties of knee joint fluid, offering pain relief and improved joint function.
- Preclinical Stage Biopharmaceuticals: SunBio is actively working on biopharmaceutical candidates targeting brain stroke and chronic anemia, aiming to address these severe health issues with innovative therapeutic solutions.
- PEG Derivatives Manufacturing: In addition to its biopharmaceutical products, SunBio also manufactures and sells PEG derivatives, showcasing its expertise in chemical synthesis and its application in medical science.
Contact Information
Address: 95, Sanbon-ro
Phone: 82 3 1423 5467
Website: https://www.sunbio.com
